Whitehawk Therapeutics 주식 (NASDAQ: WHWK)

에 대한 최신 뉴스 Whitehawk Therapeutics (NASDAQ:WHWK) 주식

Whitehawk Therapeutics

Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics Inc

Schrodinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) Software revenue growth is expected to range from 10% to 15%; Drug discovery revenue is expected to range from $45 million to $50 million.

News

Guidance

SDGR

Schrodinger Software revenue growth is expected to range from 10% to 15%; Drug discovery revenue is expected to range from $45 million to $50 million.

Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) has outperformed the market over the past 15 years by 5.68% on an annualized basis producing an average annual return of 16.77%. Currently, Verisk Analytics has a market capitalization of $43.47 billion. 
Buying $100 In VRSK: If an investor had bought $100 of VRSK stock 15 years ago, it would be worth $1,035.76 today based on a price of $309.90 for VRSK at the time of writing.
<h3>Verisk Analytics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746654312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

VRSK

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) affirms FY2025 sales outlook from $50.00 million-$53.00 million to $50.00 million-$53.00 million vs $61.78 million estimate.

Myomo Affirms FY2025 Sales Guidance of $50.00M-$53.00M vs $61.78M Est

Energy Fuels (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UUUU#AMEX">UUUU</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.05) by 160 percent. This is a 750 percent decrease over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $16.90 million which beat the analyst consensus estimate of $15.20 million by 11.17 percent. This is a 33.54 percent decrease over sales of $25.43 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

UUUU

Energy Fuels Q1 EPS $(0.13) Misses $(0.05) Estimate, Sales $16.90M Beat $15.20M Estimate

Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) sees Q2 sales of $9.000 million-$9.500 million vs $13.60 million analyst estimate.

Myomo Sees Q2 Sales $9.000M-$9.500M vs $13.60M Est

The board of directors of The Brink's Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCO#NYSE">BCO</a>) today declared a regular quarterly dividend of $0.255 cents per share on the company's common stock, an increase of 5%. The dividend is payable on June 2, 2025, to shareholders of record on May 19, 2025.&nbsp;&nbsp;

Dividends

Brink's Increases Quarterly Dividend From $0.24 To $0.255 Per Share

Schrodinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.75) by 14.67 percent. This is a 25.58 percent increase over losses of $(0.86) per share from the same period last year. The company reported quarterly sales of $59.55 million which beat the analyst consensus estimate of $54.65 million by 8.96 percent. This is a 62.72 percent increase over sales of $36.60 million the same period last year.

Schrodinger Q1 Adj. EPS $(0.64) Beats $(0.75) Estimate, Sales $59.55M Beat $54.65M Estimate

Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) affirms FY2025 sales outlook from $345.00 million-$355.00 million to $345.00 million-$355.00 million vs $350.97 million estimate.

EOLS

Evolus Affirms FY2025 Sales Guidance of $345.00M-$355.00M vs $350.97M Est

Copa Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPA#NYSE">CPA</a>) reported quarterly earnings of $4.28 per share which beat the analyst consensus estimate of $3.77 by 13.53 percent. This is a 2.15 percent increase over earnings of $4.19 per share from the same period last year. The company reported quarterly sales of $899.18 million which beat the analyst consensus estimate of $888.29 million by 1.23 percent. This is a 0.64 percent increase over sales of $893.47 million the same period last year.

Copa Holdings Q1 EPS $4.28 Beats $3.77 Estimate, Sales $899.18M Beat $888.29M Estimate

Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.30 by 63.33 percent. This is a 76.09 percent decrease over earnings of $0.46 per share from the same period last year. The company reported quarterly sales of $5.10 billion which missed the analyst consensus estimate of $5.15 billion by 0.97 percent. This is a 5.36 percent decrease over sales of $5.39 billion the same period last year.

Nutrien Q1 EPS $0.11 Misses $0.30 Estimate, Sales $5.10B Miss $5.15B Estimate

Viemed Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) reported quarterly earnings of $0.06 per share which met the analyst consensus estimate. This is a 50 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $59.13 million which missed the analyst consensus estimate of $60.60 million by 2.43 percent. This is a 16.87 percent increase over sales of $50.59 million the same period last year.

Viemed Healthcare Q1 EPS $0.06, Inline, Sales $59.13M Miss $60.60M Estimate

Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) sees Q2 sales of $121.000 million-$123.000 million vs $119.66 million analyst estimate.

GRPN

Groupon Sees Q2 Sales $121.000M-$123.000M vs $119.66M Est

Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) affirms FY2025 sales outlook from $493.00 million-$500.00 million to $493.00 million-$500.00 million vs $496.96 million estimate.

Groupon Affirms FY2025 Sales Guidance of $493.00M-$500.00M vs $496.96M Est

Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.14 by 7.14 percent. This is a 31.58 percent decrease over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $247.10 million which beat the analyst consensus estimate of $246.95 million by 0.06 percent. This is a 7.72 percent decrease over sales of $267.77 million the same period last year.

BMBL

Bumble Q1 EPS $0.13 Misses $0.14 Estimate, Sales $247.10M Beat $246.95M Estimate

5N Plus (TSX:<a class="ticker" href="https://www.benzinga.com/stock/VNP#TSX">VNP</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.06 by 83.33 percent. This is a 266.67 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $88.89 million which beat the analyst consensus estimate of $73.32 million by 21.23 percent. This is a 36.71 percent increase over sales of $65.02 million the same period last year.

TSX:VNP

5N Plus Q1 EPS $0.11 Beats $0.06 Estimate, Sales $88.89M Beat $73.32M Estimate

Trinseo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSE#NYSE">TSE</a>) reported quarterly losses of $(1.37) per share which met the analyst consensus estimate. This is a 29.38 percent increase over losses of $(1.94) per share from the same period last year. The company reported quarterly sales of $784.80 million which missed the analyst consensus estimate of $912.50 million by 13.99 percent. This is a 13.19 percent decrease over sales of $904.00 million the same period last year.

Trinseo Q1 Adj. EPS $(1.37), Inline, Sales $784.80M Miss $912.50M Estimate

GeoPark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPRK#NYSE">GPRK</a>) reported quarterly earnings of $0.25 per share which missed the analyst consensus estimate of $0.46 by 45.65 percent. This is a 54.55 percent decrease over earnings of $0.55 per share from the same period last year. The company reported $137.30 million in sales this quarter. This is a 17.98 percent decrease over sales of $167.40 million the same period last year.

GPRK

GeoPark Q1 EPS $0.25 Misses $0.46 Estimate, Sales $137.30M Down From $167.40M YoY

Plaza Retail REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PLZ#TSX">PLZ</a>) reported quarterly earnings of $0.09 per share. This is a 1.12 percent decrease over earnings of $0.09 per share from the same period last year. The company reported $31.14 million in sales this quarter. This is a 5.30 percent increase over sales of $29.57 million the same period last year.

TSX:PLZ

Plaza Retail REIT Q1 FFO $0.09 Down From $0.09 YoY, Sales $31.14M Up From $29.57M YoY

Aris Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMN#AMEX">ARMN</a>) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.17 by 5.88 percent. The company reported quarterly sales of $154.14 million which missed the analyst consensus estimate of $160.75 million by 4.11 percent.

ARMN

Aris Mining Q1 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $154.14M Miss $160.75M Estimate

Liberty Latin America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILA#NASDAQ">LILA</a>) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.07) by 885.71 percent. The company reported quarterly sales of $1.08 billion which missed the analyst consensus estimate of $1.11 billion by 2.07 percent. This is a 1.36 percent decrease over sales of $1.10 billion the same period last year.

Comments

Whitehawk Therapeutics

뉴스

에 대한 최신 뉴스 Whitehawk Therapeutics (NASDAQ:WHWK) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌